Immuneering Corporation

Direct answer

Immuneering Corporation is publicly traded on NASDAQ under the ticker IMRX.

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS...

Can you invest in Immuneering Corporation?

Yes. Immuneering Corporation is publicly traded on NASDAQ under the ticker IMRX.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Immuneering Corporation

Detailed equity research is provided by MarketSnap.